The liver cancer drugs market share will post an incremental growth of USD 5.29 billion, progressing at a CAGR of 14.67% during the forecast period. The increasing incidence of liver cancer will offer immense growth opportunities to market vendors. The liver cancer drugs market is fragmented, and the vendors are deploying growth strategies such as low-pricing strategies and strengthening the local customer base to compete in the market.
Technavio’s report on “Liver Cancer Drugs Market by Type and Geography - Forecast and Analysis 2022-2026” provides a detailed analysis of the prevalent market forces, trends, and challenges likely to impact the market in focus.
The liver cancer drugs market is segmented by Type (Immunotherapy and targeted therapy) and Geography (North America, Europe, Asia, and Rest of World (ROW))
The growth of the liver cancer drugs market size in the immunotherapy segment will be significant during the forecast period. Factors such as the development and launch of treatment therapies for liver cancer will drive the liver cancer drugs market growth in North America. 42% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for liver cancer drugs in North America.
The increasing incidence of liver cancer will directly influence the sales of the liver cancer drugs market. In addition, the use of MAbs is a liver cancer drugs market is one of the major liver cancer drugs market trends that will positively impact the market growth. However, factors such as the only curative option being surgical resection and transplantation will hamper the liver cancer drugs market growth.
The market is fragmented due to the presence of several players. Some of the major liver cancer drugs market vendors are Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc.
To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions.
Download the Free PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth.
Precise market size estimation during the forecast period 2022-2026.
CAGR of the liver cancer drugs market forecast during 2022-2026.
Market-level data on units, average selling prices, and values of the liver cancer drugs market share.
Prediction on the upcoming trends, drivers, and factors that challenge the growth of the liver cancer drugs market.
Liver cancer drugs industry growth across North America, Europe, Asia, and Rest of World (ROW).
